A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

Trial Profile

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Interim results (n=94) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 29 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 29 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top